ArticleAmerican journal of translational research2025
Efficacy and quality of life benefits of dexamethasone in advanced non-small cell lung cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of dexamethasone (Dex) on treatment outcomes in chemotherapy-treated advanced non-small cell lung cancer (NSCLC) patients.
methodsA total of 123 advanced NSCLC patients undergoing chemotherapy were enrolled. The control group received chemotherapy alone, while the research group was administered Dex in combination with chemotherapy. Short-term treatment efficacy, adverse reaction rates, humoral immunity, vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1α (HIF-1α), quality of life, and treatment adherence were compared between the two groups. Univariate and multivariate analyses were performed to identify variables influencing short-term treatment efficacy.
resultsThe two groups were equivalent in the objective response rate, disease control rate, and overall side effects rate (all P > 0.05), though the incidences of nausea/vomiting were reduced (P < 0.05). Post-treatment evaluations revealed elevated humoral immunity markers, improved quality of life scores, and better treatment adherence in the research group (all P < 0.05). Furthermore, VEGF and HIF-1α expression were suppressed in the research group (both P < 0.05). Regression analysis identified Eastern Cooperative Oncology Group Performance Status (ECOG PS; OR=2.277), VEGF (OR=5.241), and HIF-1α (OR=2.687) as independent factors influencing short-term treatment efficacy (all P < 0.05).
conclusionDex administration in chemotherapy-treated advanced NSCLC patients improves clinical outcomes and enhances quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.